Tropomyosin receptor kinase A

From WikiMD's Medical Encyclopedia

Revision as of 03:47, 22 March 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Tropomyosin receptor kinase A (TrkA), also known as nerve growth factor receptor (NGFR), is a protein that in humans is encoded by the NTRK1 gene. TrkA is a member of the tropomyosin-related kinase (Trk) family of tyrosine kinase receptors, which are key regulators in the development and maintenance of the nervous system. TrkA specifically binds to and is activated by nerve growth factor (NGF), leading to cellular differentiation and survival signals, particularly in neural cells.

Function

TrkA plays a critical role in the development and function of the nervous system. Upon binding with its ligand, NGF, TrkA undergoes dimerization and autophosphorylation, which activates its kinase activity. This activation leads to the phosphorylation of downstream signaling molecules involved in the PI3K/AKT and MAPK/ERK pathways, which are crucial for cell survival, differentiation, and growth. TrkA signaling is essential for the survival and maintenance of sympathetic and sensory neurons during development and in adult organisms.

Clinical Significance

Alterations in TrkA signaling have been implicated in a variety of human diseases. Overexpression or mutation of the NTRK1 gene can lead to the development of cancers, including certain types of thyroid cancer and neuroblastoma. Conversely, reduced expression or activity of TrkA has been associated with increased susceptibility to neurodegenerative diseases, such as Alzheimer's disease, due to the loss of trophic support for neurons.

In addition to its role in disease, TrkA is a potential therapeutic target. Agonists of TrkA are being explored for their potential to promote neuronal survival and regeneration, which could be beneficial in treating neurodegenerative conditions and nerve injury. Conversely, TrkA antagonists and kinase inhibitors are being investigated for their potential in cancer therapy, to inhibit the growth of tumors that rely on TrkA signaling for survival and proliferation.

Genetics

The NTRK1 gene, located on chromosome 1q21-q22, encodes the TrkA protein. Mutations in this gene can lead to congenital insensitivity to pain with anhidrosis (CIPA), a rare genetic disorder characterized by the inability to feel pain and temperature, and decreased or absent sweating (anhidrosis). This condition highlights the importance of TrkA in the development and function of the sensory and sympathetic nervous systems.

See Also

References

<references />


Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.